Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06173310 · ClinicalTrials.gov registry record · NA
DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer
A NA study of Borderline-resectable Pancreatic Cancer, sponsored by Ohio State University.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT06173310 is a NA study of Borderline-resectable Pancreatic Cancer that is actively recruiting participants, run by Ohio State University. The registered enrollment target is 50 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06173310, a NA study of Borderline-resectable Pancreatic Cancer, is actively recruiting participants, sponsored by Ohio State University.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research team has been studying a cutting-edge imaging technique named dynamic contrast-enhanced magnetic resonance imaging, or DCE-MRI, for over 10 years. This technique has been globally used to calculate the blood flow of various tissues, including tumors. Blood flow often serves as a critical indicator showing a disease status. For example, a pancreatic tumor typically has low blood flow, so it can be used as an indicator to identify the presence of a pancreatic tumor. In addition, an effective therapy can result in the increase of blood flow in a pancreatic tumor during the early period of treatment. Therefore, the investigators may be able to determine whether the undergoing therapy is effective or not by measuring the change of blood flow in the pancreatic tumor and deciding whether to continue the therapy or try a different one.
Conditions Studied
Interventions
- DEVICE Point-of-care Portable Perfusion Phantom (P4)
Study Locations (2)
Indiana
- Indiana University Medical Center - Indianapolis
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-10-10 |
| Est. Completion | 2029-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06173310
The ClinicalTrials.gov registry entry for NCT06173310 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Borderline-resectable Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Point-of-care Portable Perfusion Phantom (P4) is the first listed.
NCT06173310 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Indiana, Ohio.
Frequently Asked Questions
What is clinical trial NCT06173310 about?
NCT06173310 is a clinical study titled "DCE-MRI Guided Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer". The goal of this study is to test whether chemotherapy guided by a new imaging method named DCE-MRI can more effectively reduce a pancreatic tumor, enabling curable surgery, over the conventional method when a tumor is categorized as borderline resectable pancreatic cancer. UAB radiological research...
What is the current status of trial NCT06173310?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2024-10-10. Estimated completion is 2029-03.
What conditions does trial NCT06173310 study?
This clinical trial studies the following conditions: Borderline-resectable Pancreatic Cancer.
What interventions are being tested in trial NCT06173310?
The interventions under investigation include: Point-of-care Portable Perfusion Phantom (P4) (DEVICE).
Who is sponsoring clinical trial NCT06173310?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06173310 being conducted?
This trial has 2 study locations across Indiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.